UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000040991
Receipt number R000046806
Scientific Title Safety study of endoscopic intragastric balloon placement for obese patients with endocrine and metabolic diseases
Date of disclosure of the study information 2020/07/02
Last modified on 2020/07/02 21:53:35

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Safety study of endoscopic intragastric balloon placement for obese patients with endocrine and metabolic diseases

Acronym

Safety study of endoscopic intragastric balloon placement for obese patients with endocrine and metabolic diseases

Scientific Title

Safety study of endoscopic intragastric balloon placement for obese patients with endocrine and metabolic diseases

Scientific Title:Acronym

Safety study of endoscopic intragastric balloon placement for obese patients with endocrine and metabolic diseases

Region

Japan


Condition

Condition

Obese patients with any of the metabolic disorders (diabetes, hypertension, dyslipidemia are diagnosed according to the diagnostic criteria of the Japan Diabetes Society, The Japanese Society of Internal Medicine, Japanese Atherosclerotic Disease Prevention Guidelines)

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Before and after endoscopic intragastric balloon placement, we analyze the quantitative evaluation of diabetes, hypertension, and NASH subtypes over time, in addition to the presence or absence of accidents.
The primary endpoint is the safety of endoscopic intragastric balloon placement.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Safety of endoscopic intragastric balloon placement

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

N/A

Key exclusion criteria

N/A

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Shuichi
Middle name
Last name Kaneko

Organization

Kanazawa university

Division name

Gastroenterology

Zip code

920-8641

Address

13-1 Takaramachi, Kanazawa City, Ishikawa Prefecture

TEL

076-265-2235

Email

tohayashi@m-kanazawa.jp


Public contact

Name of contact person

1st name Tomoyuki
Middle name
Last name Hayashi

Organization

Kanazawa university

Division name

Gastroenterology

Zip code

920-8641

Address

13-1 Takaramachi, Kanazawa City, Ishikawa Prefecture

TEL

076-265-2235

Homepage URL


Email

tohayashi@m-kanazawa.jp


Sponsor or person

Institute

Kanazawa university

Institute

Department

Personal name



Funding Source

Organization

Japan Science and Technology Agency

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kanazawa University Advanced Medical Center

Address

13-1 Takaramachi, Kanazawa City, Ishikawa Prefecture

Tel

076-265-2000

Email

hpsangak@adm.kanazawa-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 07 Month 02 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2019 Year 11 Month 18 Day

Date of IRB

2019 Year 11 Month 18 Day

Anticipated trial start date

2019 Year 11 Month 18 Day

Last follow-up date

2023 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Major eligibility criteria: BMI27.5 kg/m2 or more with metabolic abnormality
Timing of registration: After obtaining consent for treatment
Randomization timing: No randomization
Number of cases: 10 cases
Registration period: March 31, 2022 from the date of approval
Outline of treatment contents: Place the balloon in the stomach endoscopically.
Treatment period: 1 day
Effectiveness judgment period: 2 weeks, 1 month, 3 months, 6 months after indwelling of the balloon in the stomach
Trial Phase: Phase I
Randomization: None
Specific clinical research or non-specific clinical research: Specific clinical research


Management information

Registered date

2020 Year 07 Month 02 Day

Last modified on

2020 Year 07 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046806


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name